WST monthly performance report
Monthly WST research: returns, drawdown, relative strength, seasonality, and key stats.
WST monthly report
—
Key takeaways
- West Pharmaceutical Services (WST) closed August 2026 at $351.02, up 2.95% for the month and +46.96% over the trailing 12 months.
- Year-to-date, WST is +27.58%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +23.13% versus its 200-day moving average ($285.07), a bullish technical signal.
- Over the past three years, WST has underperformed the S&P 500 by −78.70%, with a relative strength index reading of 54.3.
- Win rate over the trailing 39 months stands at 53.8% — 21 positive months versus 18 negative months.
West Pharmaceutical Services ended August 2026 at $351.02, posting a monthly return of +2.95%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −0.10%.
The current quarter stands at −3.89% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +23.13% versus the 200-day moving average ($285.07).
Year-to-date, WST is +27.58% against SPY +12.89%, a gap of +14.69%. The stock is currently −8.21% below its 52-week high, with maximum 3-year drawdown at −53.90%.
| Period | WST | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.65% | −0.20% | +0.85% |
| 1 Week | +4.16% | +3.90% | +0.26% |
| 1 Month | +2.95% | +3.05% | −0.10% |
| 3 Months | +17.95% | +7.11% | +10.84% |